The Effects of Co-admin of Colesevelam and Sitagliptin on Glucose Metabolism in Subjects With Type 2 Diabetes Mellitus

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-03-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with T2DM inadequately controlled by diet and exercise

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846

Diabetes Mellitus, Type 2

COMPLETED PHASE2

Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin

NCT01422590

Type 2 Diabetes Mellitus

COMPLETED PHASE1

Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM

NCT00820573

Diabetes

COMPLETED PHASE4

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

NCT00830076

Type 2 Diabetes Mellitus

COMPLETED PHASE1

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

NCT01462266

Type 2 Diabetes Mellitus

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The hypothesis is that co-administrationof colesevelam plus sitagliptin results in a greater reduction in HbA1c compared to colesevelam HCl treatment by

1. improving the effects of colesevelam on fasting glucose metabolism
2. improving the effects of colsevelam on postprandial glucose metabolism

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Colesevelam HCl: 3 tablets, 2x/day

Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

Group Type ACTIVE_COMPARATOR

Colesevelam HCl

Intervention Type DRUG

Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

Colesevelam plus Sitagliptin

Colesevelam: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

Sitagliptin: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

Group Type ACTIVE_COMPARATOR

Colesevelam HCl

Intervention Type DRUG

Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

Sitagliptin

Intervention Type DRUG

Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colesevelam HCl

Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.

Intervention Type DRUG

Sitagliptin

Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Welchol Januvia

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female
* Females of childbearing potential are on approved birth control method
* Negative pregnancy testing for females of childbearing potential
* Previously diagnosed or newly diagnosed with T2DM drug naïve subjects
* HbA1c: 6.7-10%
* Age 18 - 80 years
* BMI ≥ 18.5 kg/m2 and ≤ 40 kg/m2
* Fasting serum glucose \< 300 mg/dL
* Normal liver function, normal thyroid function, no history of liver, biliary or intestinal disease
* Normal TSH
* On stable diet and exercise routine for at least 4 weeks prior to screening
* Has had a stable weight (+/-5%) for ≥3 months before screening

Exclusion Criteria

* A history of type 1 diabetes mellitus or history of diabetic ketoacidosis
* History of chronic (required daily for \> 2 months) use of insulin therapy
* Treatment with blood pressure lowering therapy that has not been stable for three months before screening
* Treatment with lipid lowering medication other than statins
* Treatment with statins that has not been stable for three months before screening
* Treatment with a DPP-4 inhibitor or and GLP1 agonists at any time
* Treatment with a thiazolidinedione (TZD) within the last 6 months of screening
* History of an allergic or toxic reaction to sitagliptin or colesevelam
* History of dysphagia, swallowing disorders, bowel obstruction, intestinal motility disorder, and gastrointestinal disorders
* History of major gastrointestinal surgery
* History of kidney problems
* Fasting plasma triglycerides \> 300 mg/dL
* Serum LDL-C \<60 mg/dL
* Positive toxicology test
* Known hypersensitivity to colesevelam HCl or sitagliptin.
* Any contraindications to a study medication (colesevelam HCl or sitagliptin).

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No